Phase III booster study of GSK 10-valent pneumococcal conjugate vaccine versus Prevenar in previously primed children

Phase 3, open-label trial of pneumococcal polysaccharide conjugate vaccine (10-valent, adsorbed) and pneumococcal 7-valent conjugate vaccine in pneumococcal disease, meningococcal disease and Haemophilus influenzae type b disease (Hib) (2 arms), sponsored by GSK. Primary endpoints: Post-immunization febrile reactions and Safety. Started Feb 2007; status: completed.